General MedicationsIMPLANTATIONStandard
SINUVA
MOMETASONE FUROATE
Standard Dose
1.35MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview SINUVA is listed in Drugs@FDA under application 209310 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient MOMETASONE FUROATE Form and strength IMPLANT;IMPLANTATION - 1.35MG Sponsor INTERSECT ENT INC Submission history Latest submission status date: 2023-01-20 00:00:00.
Structured Monograph
Clinical summary
Approval overview SINUVA is listed in Drugs@FDA under application 209310 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient MOMETASONE FUROATE Form and strength IMPLANT;IMPLANTATION - 1.35MG Sponsor INTERSECT ENT INC Submission history Latest submission status date: 2023-01-20 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.